Feb 27, 2023 To consolidate or not, and the impact on negotiations in a joint venture context By Richard Thexton Patrick Ko Alon Gordon Richard Johnson +1 more... Show less When forming a joint venture or a consortium (JV), each party is likely to have a specific view about whether or not they wish to...
Feb 22, 2023 UK AGM Season – Hot Topics for 2023 By Annie Whiteside Olivia Mackay Vanessa Jakovich Alice Greenwell Rós Ní Dhubháin +2 more... Show less Over the past few weeks we have been speaking to clients on some of the key trends and developments for UK listed companies in the 2023...
Feb 21, 2023 The SEC Proposes Rule 192 Preventing Securitization Participants from entering into “Conflicted Transactions” By Brian Rance Andrew Heathcote Joana Fragata Francesca Loreto +1 more... Show less On January 25, 2023, the Securities and Exchange Commission (SEC) published proposed Rule 192 pursuant to Section 27B of the Securities...
Feb 14, 2023 DAX/MDAX M&A survey: 10 years of German deals By Lars Meyer Philipp Pütz How active have Germany’s 90 largest listed companies been in the global M&A market in recent years? Our latest survey of the last decade...
Feb 07, 2023 EU foreign subsidy control – consultation on implementing rules By Merit Olthoff Paul van den Berg Sarah Erne Joanna Goyder Malte Symann Christopher Sickinger +3 more... Show less Yesterday the European Commission put out for consultation a draft Implementing Regulation on proceedings pursuant to the Foreign...
Feb 07, 2023 The Edinburgh Reforms – FAQs By Tom Godwin Jennifer McCarthy As issuers and investors get to grips with the reforms announced by the UK Chancellor in December 2022 (including a policy note and...
Feb 06, 2023 The Long Arm of the Law – US Issues in Cross-Border Public M&A By Doug Smith Ethan Magid Katie Bentel Jennifer Brokamp +1 more... Show less There’s no escaping it – US securities and tender offer laws are implicated in essentially every public M&A deal, no matter where in the...
Feb 01, 2023 Life sciences - what to expect in 2023 By Adam Golden Harriet Hanks We anticipate a year of reserved optimism in the life sciences industry for 2023. Despite uncertain financial markets and pricing...